LONDON, Nov. 2, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) today announces that it will be presenting at the upcoming SG Cowen and Rodman & Renshaw healthcare conferences. The presentations will include the recently announced promising preliminary phase II data on AS1404 in lung cancer.
Antisoma's Chief Executive Officer, Glyn Edwards, will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference in New York at 8.20am EST on Tuesday 8 November. A live webcast of the presentation will be available on Antisoma's website www.antisoma.com. It is recommended that viewers log on 15 minutes early in order to register and download any necessary software. A recorded replay of the presentation will be available for 90 days.
Antisoma's Chief Financial Officer, Raymond Spencer, will present at the SG Cowen & Co. 6th Annual Global Health Care Conference in Barcelona, Spain, at 10.55am CET on Wednesday 9 November.
Background on Antisoma
Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Antisoma has a broad strategic alliance with Roche to develop and commercialise products from its pipeline. Please visit www.antisoma.com for further information.